24.10.2016 • News

Clariant Opens US PP Catalysts Plant

Clariant’s CEO, Hariolf Kottmann, described the investment as a...
Clariant’s CEO, Hariolf Kottmann, described the investment as a “significant step forward” for its catalysts business unit.

Swiss specialty chemicals producer Clariant has opened a new PP catalyst production facility in Louisville, Kentucky, USA, as part of a strategy to accelerate its growth in North America. The new plant has been developed and implemented in cooperation with CB&I and is part of a long-term strategic partnership with the US contractor’s Novolen PP technology business. CB&I’s Novolen gas-phase process is based on Ziegler-Natta and metallocene catalysts and produces a full range of homopolymer and random copolymer resins.

The facility, which combines sales, technical service, R&D, a technical center, pilot plants and production, is now Clariant’s largest US production hub for catalysts and further strengthens Louisville as the most important site for its regional business, the Muttenz-headquartered group said. Clariant’s CEO, Hariolf Kottmann, described the investment as a “significant step forward” for its catalysts business unit. The Swiss group has expanded its presence in North America in recent years, with sales increasing from $939 million in 2011 to $1.12 billion in 2015.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read